Announcements Trials
Browse Landscape

Status

Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Myeloproliferative Syndrome, Transient 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 6Cisplatin 5infigratinib 2Platinum 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2ricolinostat 1niraparib 1lenvatinib 1galactomannan 1fludarabine 1famitinib 1dostarlimab 1atezolizumab 1aldesleukin 1Taxes 1Standard of Care 1Sildenafil Citrate 1Sevoflurane 1Photochemotherapy 1Oxaliplatin 1Observation 1NVP-BKM120 1Interviews as Topic 1IMC-001 1Electroporation 1Desflurane 1Cyclophosphamide 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Cholangiocarcinoma × Observation × Clear all
NCT05292443 2024-02-23

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Geneplus-Beijing Co. Ltd.

Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡